Literature DB >> 22085272

The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.

Roza Zandi1, Kai Xu, Hans S Poulsen, Jack A Roth, Lin Ji.   

Abstract

The candidate tumor suppressor fragile histidine traid (FHIT) is frequently inactivated in small cell lung cancer (SCLC). Mutations in the p53 gene also occur in the majority of SCLC leading to the accumulation of the mutant protein. Here we evaluated the effect of FHIT gene therapy alone or in combination with the mutant p53-reactivating molecule, PRIMA-1(Met)/APR-246, in SCLC. Overexpression of FHIT by recombinant adenoviral vector (Ad-FHIT)-mediated gene transfer in SCLC cells inhibited their growth by inducing apoptosis and when combined with PRIMA-1(Met)/APR-246, a synergistic cell growth inhibition was achieved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22085272      PMCID: PMC3372907          DOI: 10.3109/07357907.2011.626475

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  39 in total

1.  Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells.

Authors:  H Ishii; K R Dumon; A Vecchione; F Trapasso; K Mimori; H Alder; M Mori; G Sozzi; R Baffa; K Huebner; C M Croce
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

2.  Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.

Authors:  Yin Li; Yuehua Mao; Paul W Brandt-Rauf; Ann C Williams; Robert L Fine
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

3.  FHIT gene expression is repressed by mitogenic signaling through the PI3K/AKT/FOXO pathway.

Authors:  Kevin Kelley; Steven J Berberich
Journal:  Am J Cancer Res       Date:  2011       Impact factor: 6.166

4.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Eur J Biochem       Date:  1981-03-16

5.  Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells.

Authors:  R Wu; D C Connolly; R L Dunn; K R Cho
Journal:  J Natl Cancer Inst       Date:  2000-02-16       Impact factor: 13.506

6.  The tumor spectrum in FHIT-deficient mice.

Authors:  N Zanesi; V Fidanza; L Y Fong; R Mancini; T Druck; M Valtieri; T Rüdiger; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

7.  A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

Authors:  T C Chou; P Talalay
Journal:  J Biol Chem       Date:  1977-09-25       Impact factor: 5.486

8.  Effect of fragile histidine triad gene transduction on proliferation and apoptosis of human hepatocellular carcinoma cells.

Authors:  Rong-Hua Xu; Liang-Yan Zheng; Dong-Lei He; Jian Tong; Li-Ping Zheng; Wu-Ping Zheng; Jin Meng; Li-Ping Xia; Cong-Jun Wang; Ji-Lin Yi
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

9.  Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-alpha on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells.

Authors:  J F Charlot; M Nicolier; J L Prétet; C Mougin
Journal:  Apoptosis       Date:  2006-05       Impact factor: 4.677

10.  In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.

Authors:  Hong Shi; Jeremy M R Lambert; Agnes Hautefeuille; Vladimir J N Bykov; Klas G Wiman; Pierre Hainaut; Claude Caron de Fromentel
Journal:  Carcinogenesis       Date:  2007-11-28       Impact factor: 4.944

View more
  5 in total

1.  High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.

Authors:  Roberto Jose Diaz; Mustafa Guduk; Rocco Romagnuolo; Christian A Smith; Paul Northcott; David Shih; Fitim Berisha; Adrienne Flanagan; David G Munoz; Michael D Cusimano; M Necmettin Pamir; James T Rutka
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

2.  Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo.

Authors:  Chandrashekhar D Kamat; Ron B Shmueli; Nick Connis; Charles M Rudin; Jordan J Green; Christine L Hann
Journal:  Mol Cancer Ther       Date:  2013-01-30       Impact factor: 6.261

Review 3.  Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.

Authors:  Vladimir J N Bykov; Qiang Zhang; Meiqiongzi Zhang; Sophia Ceder; Lars Abrahmsen; Klas G Wiman
Journal:  Front Oncol       Date:  2016-02-03       Impact factor: 6.244

4.  FHIT down-regulation was inversely linked to aggressive behaviors and adverse prognosis of gastric cancer: a meta- and bioinformatics analysis.

Authors:  Hua-Chuan Zheng; Li-Li Liu
Journal:  Oncotarget       Date:  2017-11-03

5.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.

Authors:  Jinfeng Liu; William Lee; Zhaoshi Jiang; Zhongqiang Chen; Suchit Jhunjhunwala; Peter M Haverty; Florian Gnad; Yinghui Guan; Houston N Gilbert; Jeremy Stinson; Christiaan Klijn; Joseph Guillory; Deepali Bhatt; Steffan Vartanian; Kimberly Walter; Jocelyn Chan; Thomas Holcomb; Peter Dijkgraaf; Stephanie Johnson; Julie Koeman; John D Minna; Adi F Gazdar; Howard M Stern; Klaus P Hoeflich; Thomas D Wu; Jeff Settleman; Frederic J de Sauvage; Robert C Gentleman; Richard M Neve; David Stokoe; Zora Modrusan; Somasekar Seshagiri; David S Shames; Zemin Zhang
Journal:  Genome Res       Date:  2012-10-02       Impact factor: 9.043

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.